Skip to content

Restylane Lyft

by Acre Pharma Limited

Restylane Lyft is a dermal tissue reconstructive material (FDA Class III; FDA product code LMH, Implant, Dermal, For Aesthetic Use) made by Acre Pharma Limited, listed in FDA GUDID since 19 Nov 2020 (UDI-DI 05060604130072), registry data as of 22 Oct 2026.

Listed FDA GUDID listing, no authorization on record

Valid until

Not applicable

Database listing, no authorization

FDA recalls

Not checked

No FDA submission to match recalls against

Documents

None

No authorization documents

Trust

Unverified

Source GUDID, synced 22 Oct 2026.

Regulatory status

as of registry sync 22 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesGUDID listing Number05060604130072 UDI-DI Date19 Nov 2020ListedStatusListed GUDID: in commercial distribution

Official records

From the FDA record

MRI safety
Labeling does not contain MRI Safety Information
Natural rubber latex
No latex statement on the label
Sterility
Supplied sterile

From the GUDID record (AccessGUDID), as read on 22 Oct 2026, as the labeller entered it.

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — GUDID listing Listed

Specification

GUDID

Generic name
Dermal tissue reconstructive material, animal-derived
Primary DI / UDI-DI
05060604130072
FDA product code
LMH
GMDN term
Dermal tissue reconstructive material, animal-derived
Device class
Class III
GUDID distribution status
In Commercial Distribution

Similar devices

Other devices filed under FDA product code LMH (Implant, Dermal, For Aesthetic Use).

Other devices from Acre Pharma Limited

See all devices from Acre Pharma Limited →

Properties

  • Supplied sterile
  • Single use
  • Implantable
  • Prescription use
  • Lot / batch number
  • Expiration date
Other properties (9, all answered No)